PRECISION: LUNG CANCER
Start:
Tue, 13 Sep 2016, 08:00
End:
Wed, 14 Sep 2016, 06:00
Website:
Venue:
Exhibit
Symposia
Workshops
Organiser
Sponsor
SCOPE OF THE MEETING
The global market for Lung cancer therapeutics, currently valued at $5 billion is poised to reach $15.1 billion by 2023, expanding by a CAGR of 12%
Learning Objectives
HIGHLIGHTS
- ANTIBODY DRUG CONJUGATES
- IMMUNOTHERAPIES
- NOVEL APPROACHES
- BIOMARKERS
- COMPANION DIAGNOSTICS
Day One: Tuesday September 13, 2016 | |||
7:30 | REGISTRATION & COFFEE | ||
8:15 | Introduction: An Overview of the History of the Development of Targeted Therapies for Lung Cancer | ||
Antibody Drug Conjugates for Lung Cancer | |||
8:30 | TBC | ||
9:00 | Safety and efficacy of single-agent Rovalpituzumab Tesirine, a delta-like protein 3 (DLL3)-targeted ADC in recurrent or refractory small cell lung cancer | ||
9:30 | Development of Probody™ Therapeutics and Probody Drug Conjugates (PDCs) with potential for the treatment of lung cancer | ||
10:00 | Targeted Small Molecule Drug Conjugates and Companion Imaging Agents for Personalized Lung Cancer Therapy | ||
10:30 | MORNING REFRESHMENTS & SPEED NETWORKING | ||
11:20 | TBC | ||
11:50 | Spotlight: A precise companion tool from discovery to market | ||
12:00 | Extracellular Antibody Drug Conjugates Exploiting the Proximity of Two Proteins | ||
12:30 | LUNCH & NETWORKING | ||
Immunotherapies in Lung Cancer | |||
1:30 | Immunotherapy Combinations: An Overview | ||
2:00 | PD-L1 Biomarkers for Anti-PD-1/PD-L1 in lung cancers | ||
2:30 | Title TBC (PD-1 inhibition for lung cancer treatment) | ||
3:00 | AFTERNOON REFRESHMENTS & NETWORKING | ||
3:30 | Therapeutic strategy against tumor acidity induced immune-suppression: L-DOS47 a clinical candidate for lung cancer | ||
4:00 | Design of Multispecific Antibodies - Modulating T-Cell Functions for Redirected Cytotoxicity | ||
4:30 | Overriding immune Suppression and Increasing TILs Through Blockade of the Phosphatidylserine Signaling Pathway | ||
Cancer Vaccines | |||
5:00 | ADXS-NEO in Lung Cancer | ||
5:30 | Title TBD: TG4010 cancer vaccine | ||
6:00 | SUMMARY & CLOSE OF DAY ONE | ||
Day Two: Wednesday September 14, 2016 | |||
8:00 | REGISTRATION & COFFEE | ||
Immunotherapy Round Up | |||
8:30 | Opening Remarks: | ||
TBD | |||
Biomarkers & Companion Diagnostics | |||
9:00 | Overview: Biomarkers and Companion Diagnostics in Anti PD-1 / Anti PDL-1 Immunotherapy | ||
9:30 | TBD | ||
10:00 | Title TBD: Overcoming resistance with combinations | ||
10:30 | PANEL DISCUSSION & SPEED NETWORKING | ||
11:30 | TBD | ||
12:00 | Path to Prospective Patient Selection in a Phase 2 Study of Seribantumab for Heregulin-Positive NSCLC | ||
12:30 | TBD | ||
1:00 | LUNCH & NETWORKING | ||
1:30 | A pilot study to assess prognostic and predictive relevance of circulating tumor DNA and circulating tumor cells in patients with advanced small cell lung cancers. | ||
2:00 | Title TBD | ||
2:30 | TARGETING CANCER STEM CELLS | ||
TBD | |||
3:00 | AFTERNOON REFRESHMENTS & NETWORKING | ||
3:30 | TBD | ||
4:00 | Mechanism and rationale for inhibition of FASN as a novel therapy for KRAS-mutant non-small cell lung cancer patients | ||
4:30 | Targeting RNA splicing in Lung Cancer | ||
5:00 | TBC | ||
TBC | |||
5:30 | SUMMARY & CLOSE OF CONFERENCE | ||
More events
Thu, 18 Jul 2024 - Sun, 21 Jul 2024
Fri, 19 Jul 2024 - Sat, 20 Jul 2024
Sun, 21 Jul 2024 - Tue, 23 Jul 2024
Mon, 22 Jul 2024 - Fri, 26 Jul 2024
Sat, 27 Jul 2024 - Fri, 28 Jun 2024
Sun, 28 Jul 2024 - Thu, 1 Aug 2024
Thu, 1 Aug 2024 - Sat, 3 Aug 2024
Thu, 1 Aug 2024 - Sun, 4 Aug 2024
